Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Equipment
Datasets
Search by expertise, name or affiliation
Current treatment strategies for patients with hairy cell leukemia
Martin S. Tallman
*
*
Corresponding author for this work
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
16
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current treatment strategies for patients with hairy cell leukemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Therapeutic Procedure
100%
Patient
75%
Purine
50%
Cladribine
50%
Hairy Cell Leukemia
50%
Development
25%
Interferon
25%
Toxicity
25%
Combination Therapy
25%
Antibody
25%
Splenectomy
25%
Pentostatin
25%
Adenosine Deaminase
25%
Immunotoxin
25%
Pseudomonas Exotoxin
25%
INIS
patients
75%
leukemia
50%
purines
50%
therapy
25%
comparative evaluations
25%
toxicity
25%
refractories
25%
antibodies
25%
interferon
25%
pseudomonas
25%
splenectomy
25%
adenosine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cladribine
50%
Hairy Cell Leukemia
50%
Purine Derivative
50%
Toxicity
25%
Interferon
25%
Antibody
25%
Pentostatin
25%
Adenosine Deaminase
25%
Immunotoxin
25%
Pseudomonas Exotoxin
25%
Neuroscience
Purine
50%
Cladribine
50%
Antibodies
25%
Interferon
25%
CD22
25%
Adenosine Deaminase
25%
Immunotoxin
25%